CJC-1295 (without DAC) – 5mg

CJC-1295 (without DAC)—also known as Modified GRF (1-29)—is a synthetic peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH). It consists of the first 29 amino acids of GHRH, strategically modified with four amino acid substitutions to resist rapid enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). By lacking the Drug Affinity Complex (DAC), this compound allows researchers to investigate natural, physiological, and short-acting growth hormone (GH) pulses from the pituitary gland without causing prolonged elevation of baseline GH levels.

Key Features & Characteristics

• Mechanism of Action: Binds selectively to GHRH receptors on pituitary somatotropes to stimulate the synthesis and pulsatile release of growth hormone.
• Structural Optimization: Features four strategic amino acid modifications that significantly extend its metabolic stability compared to native GHRH (1-29).
• Pulsatile Dynamics: Lacks the DAC modification, ensuring a short biological half-life (~30 minutes) that preserves normal circadian GH fluctuations in animal models.
• Physical Form: Available as a highly purified, sterile-filtered lyophilized powder engineered for rapid dissolution upon reconstitution.

Primary Research Applications

• Somatotropic Secretion Prototyping: Widely utilized to study the feedback mechanisms, amplitude, and timing of natural growth hormone signaling cascades.
• Cellular Repair & Metabolism: Evaluated for its downstream capability to elevate systemic Insulin-like Growth Factor 1 (IGF-1), influencing protein synthesis and connective tissue repair.
• Lipolysis & Body Composition: Investigated in metabolic research models to observe its direct effects on adipose tissue reduction and lean muscle preservation.

For Research Use Only. Not for human consumption, therapeutic, or diagnostic use.